Cargando…

Late-onset neuromuscular disorders in the differential diagnosis of sarcopenia

BACKGROUND: Sarcopenia is the age-related loss of muscle mass and strength. Undiagnosed late-onset neuromuscular disorders need to be considered in the differential diagnosis of sarcopenia. AIM: Based on emblematic case reports and current neuromuscular diagnostic guidelines for three common late-on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hofmeister, Fabian, Baber, Lisa, Ferrari, Uta, Hintze, Stefan, Jarmusch, Stefanie, Krause, Sabine, Meinke, Peter, Mehaffey, Stefan, Neuerburg, Carl, Tangenelli, Fabiana, Schoser, Benedikt, Drey, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229316/ https://www.ncbi.nlm.nih.gov/pubmed/34172001 http://dx.doi.org/10.1186/s12883-021-02264-y

Ejemplares similares

Influence of IGF-I serum concentration on muscular regeneration capacity in patients with sarcopenia
por: Jarmusch, Stefanie, et al.
Publicado: (2021)

Exploration of mitochondrial defects in sarcopenic hip fracture patients
por: Hintze, Stefan, et al.
Publicado: (2022)

Sarcopenia: investigation of metabolic changes and its associated mechanisms
por: Marques, Jair, et al.
Publicado: (2023)

Isolation and Characterization of Primary DMD Pig Muscle Cells as an In Vitro Model for Preclinical Research on Duchenne Muscular Dystrophy
por: Donandt, Tina, et al.
Publicado: (2022)

Myotonic Dystrophy—A Progeroid Disease?
por: Meinke, Peter, et al.
Publicado: (2018)

Nuclear envelope transmembrane proteins involved in genome organization are misregulated in myotonic dystrophy type 1 muscle
por: Todorow, Vanessa, et al.
Publicado: (2023)

Nuclear Envelope Transmembrane Proteins in Myotonic Dystrophy Type 1
por: Hintze, Stefan, et al.
Publicado: (2018)

CTG-Repeat Detection in Primary Human Myoblasts of Myotonic Dystrophy Type 1
por: Hintze, Stefan, et al.
Publicado: (2021)

Transcriptome Analysis in a Primary Human Muscle Cell Differentiation Model for Myotonic Dystrophy Type 1
por: Todorow, Vanessa, et al.
Publicado: (2021)

Degeneration of muscle spindles in a murine model of Pompe disease
por: Watkins, Bridgette, et al.
Publicado: (2023)

Nuclear Small Dystrophin Isoforms during Muscle Differentiation
por: Donandt, Tina, et al.
Publicado: (2023)

Uptake of moss‐derived human recombinant GAA in Gaa (−/−) mice
por: Hintze, Stefan, et al.
Publicado: (2021)

Moss-Derived Human Recombinant GAA Provides an Optimized Enzyme Uptake in Differentiated Human Muscle Cells of Pompe Disease
por: Hintze, Stefan, et al.
Publicado: (2020)

Metabolic, fibrotic and splicing pathways are all altered in Emery-Dreifuss muscular dystrophy spectrum patients to differing degrees
por: de las Heras, Jose I, et al.
Publicado: (2022)

Evaluation of myotonometry for myotonia, muscle stiffness and elasticity in neuromuscular disorders
por: Lukas, Katharina, et al.
Publicado: (2023)

Alglucosidase alfa: 5 years of experience in late-onset Pompe disease
por: Schoser, Benedikt
Publicado: (2013)

Frequency and satisfaction of conventional and complementary or alternative therapies for neuromuscular disorders
por: Böhne, Lene Änne, et al.
Publicado: (2023)

CRISPR-cas gene-editing as plausible treatment of neuromuscular and nucleotide-repeat-expansion diseases: A systematic review
por: Babačić, Haris, et al.
Publicado: (2019)

The clinical relevance of outcomes used in late-onset Pompe disease: can we do better?
por: Lachmann, Robin, et al.
Publicado: (2013)

The ageing neuromuscular system and sarcopenia: a mitochondrial perspective
por: Rygiel, Karolina A., et al.
Publicado: (2016)

APP in the Neuromuscular Junction for the Development of Sarcopenia and Alzheimer’s Disease
por: Wu, Min-Yi, et al.
Publicado: (2023)

Identification of hip fracture patients at risk for postoperative mobilisation complications via handgrip strength assessment
por: Gleich, Johannes, et al.
Publicado: (2021)

Beyond the current knowledge on sarcopenia: new insight on neuromuscular factors
por: Venturelli, Massimo, et al.
Publicado: (2022)

Associations between Early Markers of Parkinson's Disease and Sarcopenia
por: Drey, Michael, et al.
Publicado: (2017)

Advanced Skeletal Muscle Mass Reduction (Sarcopenia) Secondary to Neuromuscular Disease
por: Pesola, G. R., et al.
Publicado: (2020)

Decrease of Muscle Mass in Young Patients With Neuromuscular Disease: Assessment of Sarcopenia
por: Kim, Jisoo, et al.
Publicado: (2023)

The impact of interrupting enzyme replacement therapy in late-onset Pompe disease
por: Wenninger, Stephan, et al.
Publicado: (2021)

Mutant plasminogen in hereditary angioedema is bypassing FXII/kallikrein to generate bradykinin
por: Hintze, Stefan, et al.
Publicado: (2023)

The neuromuscular junction is a focal point of mTORC1 signaling in sarcopenia
por: Ham, Daniel J., et al.
Publicado: (2020)

Self-Assessment of Mobility of People over 65 Years of Age
por: Martin, Pascal, et al.
Publicado: (2021)

A robust neuromuscular system protects rat and human skeletal muscle from sarcopenia
por: Pannérec, Alice, et al.
Publicado: (2016)

Increased MFG‐E8 at neuromuscular junctions is an exacerbating factor for sarcopenia‐associated denervation
por: Ikemoto‐Uezumi, Madoka, et al.
Publicado: (2021)

Muscle histology changes after short term vibration training in healthy controls
por: Schoser, Benedikt
Publicado: (2015)

Prediction of Sarcopenia Using Multiple Biomarkers of Neuromuscular Junction Degeneration in Chronic Obstructive Pulmonary Disease
por: Karim, Asima, et al.
Publicado: (2021)

Residual neuromuscular blockade and late neuromuscular blockade at the post-anesthetic recovery unit: prospective cohort study
por: Gonçalves, Pedro Marcos Silva e, et al.
Publicado: (2020)

Maximum inspiratory pressure as a clinically meaningful trial endpoint for neuromuscular diseases: a comprehensive review of the literature
por: Schoser, Benedikt, et al.
Publicado: (2017)

Factors associated with the severity of COVID‐19 outcomes in people with neuromuscular diseases: Data from the International Neuromuscular COVID‐19 Registry
por: Pizzamiglio, Chiara, et al.
Publicado: (2022)

Borderlines between Sarcopenia and Mild Late-Onset Muscle Disease
por: Palmio, Johanna, et al.
Publicado: (2014)

Ocular myositis: diagnostic assessment, differential diagnoses, and therapy of a rare muscle disease – five new cases and review
por: Schoser, Benedikt GH
Publicado: (2007)

Treatment of sarcopenia in nursing home residents: a scoping review protocol
por: Benzinger, Petra, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q7n08am50qvjcid9g0mf65pa9g